Oxford BioMedica’s (OXB) “Buy” Rating Reaffirmed at Liberum Capital

Liberum Capital reissued their buy rating on shares of Oxford BioMedica (LON:OXB) in a research report report published on Thursday morning, ThisIsMoney.Co.Uk reports.

Separately, Peel Hunt reissued a buy rating on shares of Oxford BioMedica in a report on Thursday.

Shares of LON OXB traded up GBX 2 ($0.03) during midday trading on Thursday, reaching GBX 625 ($8.17). 110,056 shares of the company’s stock were exchanged, compared to its average volume of 6,890,000. Oxford BioMedica has a 52-week low of GBX 461.50 ($6.03) and a 52-week high of GBX 793 ($10.36). The stock has a market capitalization of $479.87 million and a PE ratio of -53.88. The company has a debt-to-equity ratio of 10.55, a quick ratio of 1.80 and a current ratio of 2.21. The business’s fifty day moving average price is GBX 566.14 and its two-hundred day moving average price is GBX 632.36.

In related news, insider Lorenzo Tallarigo bought 482 shares of the company’s stock in a transaction dated Wednesday, September 25th. The stock was bought at an average price of GBX 554 ($7.24) per share, with a total value of £2,670.28 ($3,489.19). Also, insider Martin Diggle bought 17,953 shares of the company’s stock in a transaction dated Thursday, September 12th. The stock was bought at an average cost of GBX 577 ($7.54) per share, with a total value of £103,588.81 ($135,357.13). Over the last ninety days, insiders acquired 18,905 shares of company stock worth $10,893,339.

Oxford BioMedica Company Profile

Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments.

Recommended Story: What are some reasons analysts would give stocks a buy rating?

Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.